398 related articles for article (PubMed ID: 26016514)
1. Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis.
Hedner C; Tran L; Borg D; Nodin B; Jirström K; Eberhard J
Histopathology; 2016 Jan; 68(2):230-40. PubMed ID: 26016514
[TBL] [Abstract][Full Text] [Related]
2. Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma.
König AM; Reeh M; Dancau AM; Rathjens M; Gros S; Uzunoglu FG; Bockhorn M; Simon R; Sauter G; Marx A; Izbicki JR
Anticancer Res; 2013 Nov; 33(11):4975-82. PubMed ID: 24222138
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab.
Lee HJ; Kim JY; Park SY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
Am J Clin Pathol; 2015 Oct; 144(4):570-8. PubMed ID: 26386078
[TBL] [Abstract][Full Text] [Related]
5. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.
Lee HJ; Seo AN; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
Br J Cancer; 2015 Jan; 112(1):103-11. PubMed ID: 25349977
[TBL] [Abstract][Full Text] [Related]
7. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer.
Wang H; Li B; Liu Z; Gong J; Shao L; Ren J; Niu Y; Bo S; Li Z; Lai Y; Lu S; Gao J; Shen L
Eur J Cancer; 2018 Jan; 88():92-100. PubMed ID: 29207318
[TBL] [Abstract][Full Text] [Related]
8. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.
Gomez-Martin C; Plaza JC; Pazo-Cid R; Salud A; Pons F; Fonseca P; Leon A; Alsina M; Visa L; Rivera F; Galan MC; Del Valle E; Vilardell F; Iglesias M; Fernandez S; Landolfi S; Cuatrecasas M; Mayorga M; Jose Paulés M; Sanz-Moncasi P; Montagut C; Garralda E; Rojo F; Hidalgo M; Lopez-Rios F
J Clin Oncol; 2013 Dec; 31(35):4445-52. PubMed ID: 24127447
[TBL] [Abstract][Full Text] [Related]
9. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1).
Park SR; Park YS; Ryu MH; Ryoo BY; Woo CG; Jung HY; Lee JH; Lee GH; Kang YK
Eur J Cancer; 2016 Jan; 53():42-50. PubMed ID: 26693898
[TBL] [Abstract][Full Text] [Related]
10. Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case.
Saito T; Kondo C; Shitara K; Ito Y; Saito N; Ikehara Y; Yatabe Y; Yamamichi K; Tanaka H; Nakanishi H
Pathol Int; 2015 Jun; 65(6):309-17. PubMed ID: 25828363
[TBL] [Abstract][Full Text] [Related]
11. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
[TBL] [Abstract][Full Text] [Related]
12. Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment.
Yoon SH; Kim YH; Lee YJ; Park J; Kim JW; Lee HS; Kim B
PLoS One; 2016; 11(8):e0161278. PubMed ID: 27517841
[TBL] [Abstract][Full Text] [Related]
13. FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation.
Betts G; Valentine H; Pritchard S; Swindell R; Williams V; Morgan S; Griffiths EA; Welch I; West C; Womack C
Virchows Arch; 2014 Feb; 464(2):145-56. PubMed ID: 24306956
[TBL] [Abstract][Full Text] [Related]
14. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
[TBL] [Abstract][Full Text] [Related]
15. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
Nagatsuma AK; Aizawa M; Kuwata T; Doi T; Ohtsu A; Fujii H; Ochiai A
Gastric Cancer; 2015 Apr; 18(2):227-38. PubMed ID: 24626858
[TBL] [Abstract][Full Text] [Related]
16. EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus.
Birkman EM; Ålgars A; Lintunen M; Ristamäki R; Sundström J; Carpén O
BMC Cancer; 2016 Jul; 16():406. PubMed ID: 27387915
[TBL] [Abstract][Full Text] [Related]
17. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer.
Kurokawa Y; Matsuura N; Kimura Y; Adachi S; Fujita J; Imamura H; Kobayashi K; Yokoyama Y; Shaker MN; Takiguchi S; Mori M; Doki Y
Gastric Cancer; 2015 Oct; 18(4):691-7. PubMed ID: 25224659
[TBL] [Abstract][Full Text] [Related]
18.
Zhang L; Hamdani O; Gjoerup O; Cho-Phan C; Snider J; Castellanos E; Nimeiri H; Frampton G; Venstrom JM; Oxnard G; Klempner SJ; Schrock AB
JCO Precis Oncol; 2022 Jan; 6():e2100330. PubMed ID: 35050711
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models.
Chen H; Ye Q; Lv J; Ye P; Sun Y; Fan S; Su X; Gavine P; Yin X
Pathol Oncol Res; 2015 Sep; 21(4):947-55. PubMed ID: 25749810
[TBL] [Abstract][Full Text] [Related]
20. Human epidermal growth factor receptor-2 in oesophageal cancers: an observational study.
Al-Momani H; Barnes R; El-Hadi A; Shah R; Lewis WG; Edwards P
World J Gastroenterol; 2012 Nov; 18(44):6447-51; discussion p.6450. PubMed ID: 23197890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
